Iridium complexes as light emitting materials and organic light emitting diode device
申请人:Cheng Chien-Hong
公开号:US20050116626A1
公开(公告)日:2005-06-02
Phosphorescent iridium complexes having Formula I or Formula II:
wherein X is chosen from a monoanionic bidentate ligand; Z is chosen from an atomic group wherein Z together with the buta-1,3-diene to which Z is attached form an aryl group or heteroaryl group; R, R
1
, and R
2
are independently chosen from a hydrogen atom or a substituent; m is an integer from 0 to 4; and n is an integer from 0 to the maximum number of possible substituents on Z, are disclosed. Light emitting devices using the phosphorescent iridium complexes are also disclosed.
Rapid production of benzazole derivatives by a high-pressure and high-temperature water microflow chemical process
作者:I. Nagao、T. Ishizaka、H. Kawanami
DOI:10.1039/c6gc01195k
日期:——
A high-pressure and high-temperature (HPHT) water microflow chemical process was utilized for the synthesis of benzazolederivatives.
高压高温(HPHT)水微流化学过程被用于合成苯并唑衍生物。
Methods of treating or preventing interstitial cystitis
申请人:Eli Lilly and Company
公开号:US06025379A1
公开(公告)日:2000-02-15
This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.
Methods for treating a physiological disorder associated with
申请人:Eli Lilly and Company
公开号:US05552426A1
公开(公告)日:1996-09-03
This invention provides substituted benzimidazoles which are useful in treating or preventing conditions associated with .beta.-amyloid peptide. Some such conditions associated with .beta.-amyloid peptide include Alzheimer's Disease, Down's Syndrome and amyloidosis of the Dutch type.
This invention provides novel substituted benzimidazoles of formula II which are useful as tachykinin receptor antagonists. This invention also provides methods for treating a condition associated with an excess of tachykinin which comprises administering to a mammal in need thereof one of a series of substituted benzimidazoles. This invention further provides pharmaceutical formulations comprising one or more of the substituted benzimidazoles of the present invention in association with pharmaceutical carriers, diluents, or excipients.
A and Ra-Re are as defined in the description.